An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02560103 |
Recruitment Status :
Completed
First Posted : September 25, 2015
Last Update Posted : June 26, 2018
|
Sponsor:
Vanda Pharmaceuticals
Information provided by (Responsible Party):
Vanda Pharmaceuticals
Tracking Information | |||
---|---|---|---|
First Submitted Date | September 21, 2015 | ||
First Posted Date | September 25, 2015 | ||
Last Update Posted Date | June 26, 2018 | ||
Study Start Date | September 2015 | ||
Actual Primary Completion Date | October 2017 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures |
|
||
Original Primary Outcome Measures |
|
||
Change History | |||
Current Secondary Outcome Measures | Not Provided | ||
Original Secondary Outcome Measures | Not Provided | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title | An Observational Study to Investigate the Effects of Rapid Transmeridian Travel | ||
Official Title | An Observational Study to Investigate the Effects of Rapid Travel | ||
Brief Summary | Observational study to investigate circadian rhythm patterns | ||
Detailed Description | Not Provided | ||
Study Type | Observational | ||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
||
Target Follow-Up Duration | Not Provided | ||
Biospecimen | Not Provided | ||
Sampling Method | Non-Probability Sample | ||
Study Population | Healthy volunteers | ||
Condition | Jet Lag Disorder | ||
Intervention | Other: Transmeridian travel across multiple time zones | ||
Study Groups/Cohorts | Single group
No treatment
Intervention: Other: Transmeridian travel across multiple time zones
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status | Completed | ||
Actual Enrollment |
119 | ||
Original Estimated Enrollment |
25 | ||
Actual Study Completion Date | October 2017 | ||
Actual Primary Completion Date | October 2017 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years to 75 Years (Adult, Older Adult) | ||
Accepts Healthy Volunteers | Yes | ||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries | United States | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number | NCT02560103 | ||
Other Study ID Numbers | VP-VEC-162-0101 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Current Responsible Party | Vanda Pharmaceuticals | ||
Original Responsible Party | Same as current | ||
Current Study Sponsor | Vanda Pharmaceuticals | ||
Original Study Sponsor | Same as current | ||
Collaborators | Not Provided | ||
Investigators | Not Provided | ||
PRS Account | Vanda Pharmaceuticals | ||
Verification Date | June 2018 |